Drugs

, Volume 59, Supplement 4, pp 19–27

Clinical Pharmacokinetics and Administration of Established Platinum Drugs

  • Peter J. O'Dwyer
  • James P. Stevenson
  • Steven W. Johnson
Review Article

Abstract

We review the pharmacology and clinical administration of the commonly used platinum-based anticancer drugs cisplatin and carboplatin, and the more recently approved diamminocyclohexane-based oxaliplatin. The development of analogues of cisplatin has been focused upon identifying compounds with less toxicity and with a different spectrum of activity.

Carboplatin exemplifies the former, while the initial data with oxaliplatin support its activity in cisplatin-resistant tumours. The clinical pharmacokinetics of the drugs are reviewed. Incorporation of these data into the design of clinical regimens has permitted individualised therapy with carboplatin, and has enhanced safety. Additional investigation of the pharmacodynamics of all of these agents is expected to result in their selective application. The clinical effects of these analogues are discussed.

References

  1. 1.
    Loehrer P, Einhorn L. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100: 704–13Google Scholar
  2. 2.
    Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39: 1357–61PubMedCrossRefGoogle Scholar
  3. 3.
    Hayes D, Cvitkovic E, Golbey R, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–81PubMedCrossRefGoogle Scholar
  4. 4.
    Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society Clinical Oncology. J Clin Oncol 1999; 17: 2971–94Google Scholar
  5. 5.
    Connors T, Jones M, Ross W, et al. New platinum complexes with anti-tumour activity. Chem Biol Interact 1972; 5: 415–24PubMedCrossRefGoogle Scholar
  6. 6.
    Harrap K. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985; 12: A21–A33CrossRefGoogle Scholar
  7. 7.
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56PubMedGoogle Scholar
  8. 8.
    Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages 3 and 4 ovarian cancer. J Clin Oncol 1992; 10: 706–17PubMedGoogle Scholar
  9. 9.
    Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours: a multiinstitutional study. J Clin Oncol 1993; 11(4): 598–606PubMedGoogle Scholar
  10. 10.
    De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-MO head and neck cancer. J Clin Oncol 1995; 13: 1493–500PubMedGoogle Scholar
  11. 11.
    Burchenal JH, Irani G, Kern K, et al. 1,2-diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 1980; 74: 146–55PubMedCrossRefGoogle Scholar
  12. 12.
    Chaney SG. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand. Int J Oncol 1995; 6: 1291–305PubMedGoogle Scholar
  13. 13.
    Extra JM, Espic M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303PubMedCrossRefGoogle Scholar
  14. 14.
    Tashiro R, Kawada Y, Sakuri Y, et al. Antitumor activity of a new platinum complex, oxalato (trans-I-1,2-diaminocyclohexane) platinum (II): new experimental data. Biomed Pharmacother 1989; 43: 251PubMedCrossRefGoogle Scholar
  15. 15.
    Mathe G, Kidani Y, Sekiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 1989; 43: 237–50PubMedCrossRefGoogle Scholar
  16. 16.
    Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane platinum (II) complexes. Chem Bil Interact 1989; 70: 39–49CrossRefGoogle Scholar
  17. 17.
    Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9(10): 1053–71PubMedCrossRefGoogle Scholar
  18. 18.
    Saris CP, van de Vaart PJ, Rietbroek R, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17(12): 2763–9PubMedCrossRefGoogle Scholar
  19. 19.
    Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum (II) and platinum analogues by platinumresistant murine leukemia cells in vitro. Cancer Res 1988; 48: 9–13PubMedGoogle Scholar
  20. 20.
    Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52(12): 1855–65PubMedCrossRefGoogle Scholar
  21. 21.
    Canetta R, Bragman K, Smaldone L, et al. Carboplatin: current status and future prospects. Cancer Treat Rev 1988; 15 Suppl. B: 17–32PubMedCrossRefGoogle Scholar
  22. 22.
    Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000; 59 Suppl. 4: 29–36PubMedCrossRefGoogle Scholar
  23. 23.
    Duffull S, Robinson B. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 1997; 33: 161–83PubMedCrossRefGoogle Scholar
  24. 24.
    van der Vijgh W. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242–61PubMedCrossRefGoogle Scholar
  25. 25.
    Extra J, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25: 13–22PubMedGoogle Scholar
  26. 26.
    DeConti R, Toftness B, Lange R, et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973; 33: 1310–5PubMedGoogle Scholar
  27. 27.
    Himmelstein K, Patton T, Belt R, et al. Clinical kinetic s on intact cisplatin and some related species. Clin Pharmacol Ther 1981; 29: 658–64PubMedCrossRefGoogle Scholar
  28. 28.
    Vermorken J, van der Vijgh W, Klein I, et al. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 1984; 68: 505–13PubMedGoogle Scholar
  29. 29.
    Gormley P, Bull J, LeRoy A, et al. Kinetics of cisdichlorodiammineplatinum. Clin Pharmacol Ther 1979; 25: 351–7PubMedGoogle Scholar
  30. 30.
    Belt R, Himmelstein K, Patton T, et al. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1979; 63: 1515–21PubMedGoogle Scholar
  31. 31.
    Harland S, Newell D, Siddik Z, et al. Pharmacokinetics of cisdiammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984; 44: 1693–7PubMedGoogle Scholar
  32. 32.
    Calvert A, Newell D, Gumbrell L, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56PubMedGoogle Scholar
  33. 33.
    Gamelin E, Bouil A, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997; 3: 891–9PubMedGoogle Scholar
  34. 34.
    Egorin MJ, Van Echo DA, Olman EA, et al. Prospective of validation of a pharmacologically-based dosing scheme for the cis-diamminedichloroplatin (II) analogue cis-diamminecyclobutanedicarboxylato platinum (II). Cancer Res 1985; 45: 6502–6PubMedGoogle Scholar
  35. 35.
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56PubMedGoogle Scholar
  36. 36.
    Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573–80PubMedCrossRefGoogle Scholar
  37. 37.
    Jodrell D, Egorin M, Canetta R, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520–8PubMedGoogle Scholar
  38. 38.
    Reyno L, Egorin M, Canetta R, et al. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 1993; 11: 1156–64PubMedGoogle Scholar
  39. 39.
    O'Dwyer PJ, Hamilton TC, Yao K-S, et al. Cellular pharmacodynamics of anticancer drugs. In: Schilsky R, Milano G, Ratain M, editors. Cancer pharmacology. 1996: 329–62Google Scholar
  40. 40.
    Reed E, Ozols RF, Tarone R, et al. Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84: 5024–8PubMedCrossRefGoogle Scholar
  41. 41.
    Schellens JHM, Ma J, Planting ASTL, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes, and tumor response in patients with solid tumors. Br J Cancer 1996; 73: 1569–75PubMedCrossRefGoogle Scholar
  42. 42.
    Schellens JHM, Ma J, Planting ASTL, et al. Adaptive intrapatient dose escalation of cisplatin. Proc Am Soc Clin Oncol 1996; 15: 178Google Scholar
  43. 43.
    Ozols RF, Ostchega Y, Myers CE, et al. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246–50PubMedGoogle Scholar
  44. 44.
    Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal Cisdiamminedichloroplatin with synthetic thiosulfate protection. Cancer Res 1983; 43: 1426–31PubMedGoogle Scholar
  45. 45.
    Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950–5PubMedCrossRefGoogle Scholar
  46. 46.
    Solomon B, Soulen MC, Baum RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Intervent Radiol 1999; 10: 793–8CrossRefGoogle Scholar
  47. 47.
    Evans BD, Raju KS, Calvert AH, et al. Phase II study of JM8, a new platinum analog, in ovarian cancer. Cancer Treat Rep 1983; 67: 997–1000PubMedGoogle Scholar
  48. 48.
    Ozols RF, Behrens BC, Ostchega Y, et al. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 1985; 12: 59–65PubMedCrossRefGoogle Scholar
  49. 49.
    Levi F, Giachetti S, Adam R, et al. Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 1995; 31A: 1264–70PubMedCrossRefGoogle Scholar
  50. 50.
    McMahon SB, Priestley JV. Peripheral neuropathies and neurotrophic factors. Animal models and clinical perspectives. Curr Opin Neurobiol 1995; 5: 616–24CrossRefGoogle Scholar
  51. 51.
    Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1995; 13: 1860–70PubMedGoogle Scholar
  52. 52.
    Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (L-OHP): Global safety in 682 patients. Proc Am Soc Clin Oncol 1995; 14: 209Google Scholar
  53. 53.
    Extra J, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Peter J. O'Dwyer
    • 1
  • James P. Stevenson
    • 1
  • Steven W. Johnson
    • 1
  1. 1.University of Pennsylvania Cancer CenterPhiladelphiaUSA

Personalised recommendations